Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F15%3A%230000215" target="_blank" >RIV/26475821:_____/15:#0000215 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3ce71c87-60c0-4dc9-ab79-97b2cbd78559&cKey=5186b725-e557-402c-bc1f-77fcbce36e41&mKey=" target="_blank" >http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3ce71c87-60c0-4dc9-ab79-97b2cbd78559&cKey=5186b725-e557-402c-bc1f-77fcbce36e41&mKey=</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases

Popis výsledku v původním jazyce

Poster describing quantitative changes of mutational KRAS burden in plasma and urinary ctDNA. Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths. Over half of patients with CRC will develop liver metastases. Surgical resection, in combination with systemic therapies, greatly improves long-term outcomes, and around 40% of patients with resected liver limited disease are alive 5 years after diagnosis. While tumor staging and radicality of surgery are commonly used for prognostic assessment, better non-invasive markers are needed for monitoring chemo-responsiveness, following minimal residual disease (MRD), and guiding complex treatment decisions in these patients. This study evaluated the utility of quantitating KRAS mutation burden in urinary and plasma ctDNA as a means of monitoring MRD in surgical CRC patients with liver limited metastases. We demonstrate for the first time that quantitative changes of mutational KRAS burde

Název v anglickém jazyce

Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases

Popis výsledku anglicky

Poster describing quantitative changes of mutational KRAS burden in plasma and urinary ctDNA. Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths. Over half of patients with CRC will develop liver metastases. Surgical resection, in combination with systemic therapies, greatly improves long-term outcomes, and around 40% of patients with resected liver limited disease are alive 5 years after diagnosis. While tumor staging and radicality of surgery are commonly used for prognostic assessment, better non-invasive markers are needed for monitoring chemo-responsiveness, following minimal residual disease (MRD), and guiding complex treatment decisions in these patients. This study evaluated the utility of quantitating KRAS mutation burden in urinary and plasma ctDNA as a means of monitoring MRD in surgical CRC patients with liver limited metastases. We demonstrate for the first time that quantitative changes of mutational KRAS burde

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13660" target="_blank" >NT13660: Hodnocení kvality multimodální péče u nemocných s jaterními metastázami kolorektálního karcinomu v rámci komplexních onkologických center ČR Multicentrická studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů